መነሻ › ክሮኒክ ሊምፎሳይቲክ ሉኬሚያ › ማሳቹሴትስ › Boston
በBoston፣ MA ለክሮኒክ ሊምፎሳይቲክ ሉኬሚያ የሚደረጉ ክሊኒካዊ ጥናቶች
ለክሮኒክ ሊምፎሳይቲክ ሉኬሚያ የሚደረጉ 31 ጥናቶች በBoston እና በአካባቢው ባሉ ቦታዎች (በወደ 30 ማይል ውስጥ) ተሳታፊዎችን እየፈለጉ ነው። ማን መሳተፍ እንደሚችል እና የጥናት ቡድኑን እንዴት መገናኘት እንደሚቻል ለማየት ጥናቱን ክፈቱ።
Official study text (English)
ለጥናት ተሳታፊዎችን እየፈለጉ ነው? በዚህ ገጽ ላይ በ$99 ለ30 ቀናት ያስቀምጡት →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
ተሳታዮችን በመፈለግ ላይደረጃ 3
- Dana-Farber Cancer Institute, Boston
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
ተሳታዮችን በመፈለግ ላይደረጃ 3
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
ተሳታዮችን በመፈለግ ላይደረጃ 3
- Beth Israel Deaconess Medical Center (Bidmc), Boston
- Dana Farber Cancer Institute, Boston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
- Dana Farber Cancer Institute, Boston
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
ተሳታዮችን በመፈለግ ላይደረጃ 3
- Dana Farber Cancer Institute, Boston
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
- Dana Farber Cancer Institute, Boston
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ተሳታዮችን በመፈለግ ላይደረጃ 3
- Dana Farber Cancer Institute, Boston
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
ተሳታዮችን በመፈለግ ላይደረጃ 2
- Dana-Farber Cancer Institute, Boston
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
- Research Site, Boston
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
ተሳታዮችን በመፈለግ ላይደረጃ 1
- Tufts Medical Center, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
- Massachusetts General Hospital, Boston
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
ተሳታዮችን በመፈለግ ላይደረጃ 4
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
ተሳታዮችን በመፈለግ ላይደረጃ 2
- Massachusetts General Hospital, Boston
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
ተሳታዮችን በመፈለግ ላይደረጃ 2
- Research Site, Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
ተሳታዮችን በመፈለግ ላይደረጃ 1ጤናማ ተሳታዮች ይቀበላሉ
- Brigham and Women's Hospital, Boston
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
ተሳታዮችን በመፈለግ ላይደረጃ 2
- Boston Medical Center, Boston
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
- Dana-Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
ተሳታዮችን በመፈለግ ላይደረጃ 1
- Dana Farber Cancer Institute, Boston
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
- Dana-Farber Cancer Institute, Boston
Understanding Chronic Lymphocytic Leukemia
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
- Dana Farber Cancer Institute, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
ተሳታዮችን በመፈለግ ላይደረጃ 2ጤናማ ተሳታዮች ይቀበላሉ
- DFCI/BWH Brigham and Women's Hospital, Boston
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
ተሳታዮችን በመፈለግ ላይደረጃ 4
- Dana-Farber Cancer Institute, Boston
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
ተሳታዮችን በመፈለግ ላይደረጃ 4
- Dana-Farber Cancer Institute, Boston
Study of SGR-1505 in Mature B-Cell Neoplasms
ተሳታዮችን በመፈለግ ላይደረጃ 1
- Beth Israel Deaconess Medical Center, Boston
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
- Dana-Farber Cancer Institute, Boston
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
ተሳታዮችን በመፈለግ ላይደረጃ 2
- Dana-Farber Cancer Institute /ID# 230061, Boston
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
ተሳታዮችን በመፈለግ ላይደረጃ 2
- Beth Israel Deaconess Medical Center, Boston
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
ተሳታዮችን በመፈለግ ላይደረጃ 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Mosunetuzumab for CLL MRD Clearance
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
ተሳታዮችን በመፈለግ ላይደረጃ 2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
ተሳታዮችን በመፈለግ ላይደረጃ 1
- Dana-Farber Cancer Institute, Boston
በሌሎች ከተሞች ለክሮኒክ ሊምፎሳይቲክ ሉኬሚያ የሚደረጉ ጥናቶች
- Columbus, OH28 ጥናቶች
- Durham, NC27 ጥናቶች
- Washington, DC22 ጥናቶች
- Seattle, WA20 ጥናቶች
- Rochester, MN19 ጥናቶች
- New York City, NY18 ጥናቶች
- Houston, TX17 ጥናቶች
- Baldwin Park, CA16 ጥናቶች
- Milwaukee, WI15 ጥናቶች
- Chicago, IL14 ጥናቶች
- Cincinnati, OH14 ጥናቶች
- Nashville, TN13 ጥናቶች
በBoston ውስጥ ያሉ ሌሎች ጥናቶች
- የጡንቻ ካንሰር111 ጥናቶች
- ኖን-ስማል ሴል የሳንባ ካንሰር90 ጥናቶች
- ካንሰር (ሁሉም ዓይነቶች)86 ጥናቶች
- የኮሎሬክታል ካንሰር63 ጥናቶች
- Metastatic Cancer63 ጥናቶች
- የሳንባ ካንሰር62 ጥናቶች
- የእንቁላል ካንሰር61 ጥናቶች
- የፕሮስቴት ካንሰር59 ጥናቶች
- ዲፕሬሽን52 ጥናቶች
- የኤንዶሜትሪየም ካንሰር50 ጥናቶች
- የልብ ድካም44 ጥናቶች
- አኩት ማይሎይድ ሊውኬሚያ44 ጥናቶች
ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።